PLYX · Polaryx Therapeutics, Inc. · Executive Compensation
$2.07
-0.01 (-0.48%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$104.18M
Shares
49.85M
Volume · Oct 5
40.07K
Avg daily vol (3M)
78.28K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alex Yang | Chief Executive Officer | $792,000 |
| Lisa Bollinger | Chief Medical Officer\ | $482,500 |
| G. Michael Landis | Chief Financial Officer | $310,667 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alex Yang | Chief Executive Officer | $580,000 |
| G. Michael Landis | Chief Financial Officer | $87,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lisa Bollinger, MD | Chief Medical Officer | Resigned | 2026-07-21 |